Renovaro Inc. (NASDAQ:RENB) Short Interest Up 27.7% in December

Renovaro Inc. (NASDAQ:RENB) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,870,000 shares, a growth of 27.7% from the November 30th total of 3,030,000 shares. Currently, 5.0% of the company’s shares are sold short. Based on an average daily trading volume, of 869,400 shares, the days-to-cover ratio is currently 4.5 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new stake in shares of Renovaro in the second quarter worth $220,000. JPMorgan Chase & Co. boosted its position in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock worth $45,000 after buying an additional 72,230 shares during the period. Barclays PLC boosted its position in shares of Renovaro by 315.7% in the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after buying an additional 52,804 shares during the period. State Street Corp grew its stake in shares of Renovaro by 3.8% in the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after buying an additional 48,114 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Renovaro during the 2nd quarter valued at about $79,000. 71.41% of the stock is owned by institutional investors and hedge funds.

Renovaro Stock Down 4.0 %

Shares of RENB stock traded down $0.04 on Tuesday, reaching $0.84. 366,774 shares of the stock were exchanged, compared to its average volume of 628,313. The stock has a market cap of $132.61 million, a P/E ratio of -0.87 and a beta of 0.65. The firm has a 50 day moving average of $0.91 and a two-hundred day moving average of $0.91. Renovaro has a 1-year low of $0.40 and a 1-year high of $5.25.

Renovaro (NASDAQ:RENB) last released its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) earnings per share for the quarter.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.